Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics
NCT00224276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2005-09-22
Summary
This pilot study hypothesizes that diagnosed and undiagnosed prevalence of diabetes mellitus may differ across antipsychotioc medications in a community mental health center. The study further hypothesizes that control of diabetes among diagnosed cases may be suboptimal.
Conditions
Sponsors & Collaborators
-
Janssen Pharmaceutica N.V., Belgium
collaborator INDUSTRY -
Yale University
lead OTHER
Principal Investigators
-
Scott W Woods, MD · Yale University
Eligibility
- Min Age
- 0 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
NCT01222793 ·Status: COMPLETED
-
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
NCT01269710 ·Status: COMPLETED
-
Antipsychotic Polypharmacy: Prevalence, Background and Consequences
NCT00541398 ·Status: COMPLETED ·Phase: NA
-
Antipsychotic Induced Structural and Functional Brain Changes
NCT02435095 ·Status: TERMINATED ·Phase: PHASE4
-
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II
NCT00377117 ·Status: COMPLETED
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
NCT03911726 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
NCT01952041 ·Status: COMPLETED ·Phase: NA
-
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
NCT00932529 ·Status: COMPLETED ·Phase: PHASE4
-
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
NCT00148590 ·Status: TERMINATED ·Phase: PHASE3
-
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population
NCT00253240 ·Status: COMPLETED
-
Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.
NCT05939765 ·Status: WITHDRAWN
-
Medication Reviews in Severe Mental Illness
NCT05243160 ·Status: COMPLETED ·Phase: NA
-
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
NCT01029769 ·Status: COMPLETED ·Phase: NA
-
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
NCT00206960 ·Status: COMPLETED ·Phase: NA
-
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
NCT02220504 ·Status: COMPLETED ·Phase: NA
-
Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia
NCT01034085 ·Status: COMPLETED
-
Bromocriptine for Patients With Schizophrenia and Prediabetes
NCT03575000 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy of Lu 31-130 in Patients With Schizophrenia
NCT00768326 ·Status: COMPLETED ·Phase: PHASE2
-
Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?
NCT00223522 ·Status: COMPLETED
-
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
NCT02202226 ·Status: COMPLETED ·Phase: PHASE1
-
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
NCT00148616 ·Status: TERMINATED ·Phase: PHASE3
-
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years
NCT00230893 ·Status: COMPLETED
-
A Physical Dependence Study in Schizophrenia
NCT01452919 ·Status: COMPLETED ·Phase: PHASE3
-
D-serine for the Schizophrenia Prodrome
NCT00826202 ·Status: COMPLETED ·Phase: PHASE2